Trastuzumab biosimilar - Pfizer

Drug Profile

Trastuzumab biosimilar - Pfizer

Alternative Names: PF-05280014; PF-5280014; Trastuzumab - Pfizer

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 01 Mar 2016 Pfizer completes the REFLECTION B327-04 trial in Breast cancer (Combination therapy, Early-stage disease, Neoadjuvant therapy) in US, Belarus, Italy, Hungary, Serbia, Slovakia, Ukraine, Poland, Czech Republic and Russia (NCT02187744/ EudraCT2013-004679-11)
  • 25 Nov 2014 Phase-III clinical trials in Breast cancer (First-line therapy, Metastatic disease) in USA, Romania and India (IV)
  • 04 Nov 2014 Phase-III clinical trials in Breast cancer (Combination therapy, Early-stage disease, Neoadjuvant therapy) in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top